UPTRAVI — Sales to customers (Note 9)
Johnson & Johnson UPTRAVI — Sales to customers (Note 9) decreased by 1.6% to $483.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $451.00M to $483.00M. Over 4 years (FY 2021 to FY 2025), UPTRAVI — Sales to customers (Note 9) shows an upward trend with a 11.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercial execution, while a decrease may signal competitive pressure, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of the UPTRAVI pharmaceutical product line to exter...
Peer comparison
Comparable to specific drug or product line revenue disclosures reported by other pharmaceutical companies in their segment notes.
jnj_segment_uptravi_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $313.00M | $309.00M | $310.00M | $325.00M | $328.00M | $333.00M | $336.00M | $362.00M | $399.00M | $402.00M | $419.00M | $468.00M | $426.00M | $458.00M | $465.00M | $451.00M | $476.00M | $484.00M | $491.00M | $483.00M |
| QoQ Change | — | -1.3% | +0.3% | +4.8% | +0.9% | +1.5% | +0.9% | +7.7% | +10.2% | +0.8% | +4.2% | +11.7% | -9.0% | +7.5% | +1.5% | -3.0% | +5.5% | +1.7% | +1.4% | -1.6% |
| YoY Change | — | — | — | — | +4.8% | +7.8% | +8.4% | +11.4% | +21.6% | +20.7% | +24.7% | +29.3% | +6.8% | +13.9% | +11.0% | -3.6% | +11.7% | +5.7% | +5.6% | +7.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's uptravi — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported uptravi — sales to customers (note 9) of $483.00M in Q1 2026.
- How has Johnson & Johnson's uptravi — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's uptravi — sales to customers (note 9) increased by 7.1% year-over-year, from $451.00M to $483.00M.
- What is the long-term trend for Johnson & Johnson's uptravi — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's uptravi — sales to customers (note 9) has grown at a 11.4% compound annual growth rate (CAGR), from $1.24B to $1.90B.
- What does uptravi — sales to customers (note 9) mean?
- The total revenue earned from selling the UPTRAVI drug to customers.